Hence, many conventional antiplatelet aggregation drugs are seen to be inhibitors of 5-HT2A, such as sarpogrelate, cyproheptadine, pizotifen, which are used in major occlusive disorders, such as atherosclerosis [31,32]. The gene discussed is HTR2A; the disease is atherosclerosis.